BRIEF-Sage Therapeutics announces the lancet publishes positive phase 2 brexanolone (sage-547) clinical data – Reuters


June 12 Sage Therapeutics Inc:

* Sage Therapeutics announces the lancet publishes positive
phase 2 brexanolone (sage-547) clinical data in severe
postpartum depression

* Sage Therapeutics Inc says study showed significant mean
reduction in 17-item hamilton rating scale for depression
(ham-d) total score compared to placebo

* Sage Therapeutics-70 percent of subjects in study
experienced remission of symptoms within 60 hours of treatment
with brexanolone and maintained effect until 30-day follow-up

* Sage Therapeutics Inc – brexanolone was well-tolerated in
this study with no observations of deaths, serious adverse
events or discontinuations
Source text for Eikon:
Further company coverage:

Comments

Write a Reply or Comment:

Your email address will not be published.*